Janssen-Cilag Ltd.
Janssen-Cilag Ltd.
Explore linked clinical trials.14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting | Crohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Not yet recruiting | Not stated | 2026-10-01 | NCT07851207 | |
| A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Not stated | 2026-09-25 | NCT07532226 | |
| A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK) | Crohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Not stated | 2026-09-25 | NCT07242248 | |
| Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06408935 | |
| A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | Fistulizing Crohns Disease; Perianal Crohns Disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05347095 | |
| A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-08-28 | NCT06285318 | |
| Improving Pulmonary Hypertension Screening by Echocardiography | cardiovascular disorder, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Active, not recruiting | Not stated | 2026-07-01 | NCT06038149 | |
| Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2026-04-13 | NCT06062537 | |
| Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Phase 2 | 2025-12-19 | NCT06511648 | |
| French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings | chronic lymphocytic leukemia/small lymphocytic lymphoma | Active, not recruiting | Not stated | 2025-12-03 | NCT05590702 | |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT07110662 | |
| TherApeutics in Early ProState Cancer (TAPS02) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2025-06-20 | NCT05191680 | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2024-11-12 | NCT01957436 | |
| Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 / Phase 3 | 2024-05-10 | NCT04061512 |